Strategic Advisors LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 2,616 shares of the medical research company’s stock, valued at approximately $429,000.

A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Norges Bank acquired a new position in shares of Amgen during the fourth quarter valued at $1,016,913,000. Loomis Sayles & Co. L P raised its position in Amgen by 4.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 3,001,021 shares of the medical research company’s stock valued at $438,779,000 after buying an additional 133,918 shares in the last quarter. Bank of Montreal Can raised its position in Amgen by 10.5% in the first quarter. Bank of Montreal Can now owns 2,837,456 shares of the medical research company’s stock valued at $465,543,000 after buying an additional 269,586 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in Amgen during the fourth quarter valued at approximately $275,209,000. Finally, Putnam Investments LLC raised its position in Amgen by 9.2% in the fourth quarter. Putnam Investments LLC now owns 1,557,408 shares of the medical research company’s stock valued at $227,709,000 after buying an additional 131,223 shares in the last quarter. Institutional investors own 78.80% of the company’s stock.

Shares of Amgen Inc. (NASDAQ AMGN) opened at 180.21 on Friday. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $184.21. The firm has a market cap of $132.53 billion, a PE ratio of 17.12 and a beta of 1.36. The stock’s 50 day moving average price is $169.47 and its 200-day moving average price is $165.39.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, April 26th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.15. The business had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.60 billion. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The company’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.90 EPS. On average, equities research analysts anticipate that Amgen Inc. will post $12.47 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/07/23/strategic-advisors-llc-acquires-new-position-in-amgen-inc-nasdaqamgn.html.

AMGN has been the subject of several research analyst reports. Deutsche Bank AG initiated coverage on Amgen in a research report on Friday, June 23rd. They set a “hold” rating and a $172.00 price target for the company. Credit Suisse Group restated a “hold” rating and set a $178.00 price target on shares of Amgen in a research report on Tuesday, April 4th. Vetr upgraded Amgen from a “buy” rating to a “strong-buy” rating and set a $184.82 price target for the company in a research report on Monday, March 27th. ValuEngine lowered Amgen from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Oppenheimer Holdings, Inc. set a $189.00 price target on Amgen and gave the stock a “buy” rating in a research report on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have assigned a buy rating and three have issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $185.21.

In other news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the sale, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.